Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol.

Conference item

Herein we assess the safety of an inhaled formulation of beclomethasone dipropionate (BDP) which uses the propellant hydrofluoroalkane-134a (HFA) for the treatment of asthma. Acute local tolerability (as assessed by the incidence of cough and mean forced expiratory volume after 1 s inhalation) was similar for both BDP and placebo formulated in either chlorofluorocarbon (CFC) or HFA propellants. A total of 43 patients were treated with HFA-BDP (0, 200, 400 or 800 micrograms day-1) or CFC-BDP (...

Expand abstract

Authors: Thompson, P; Davies, R; Young, W; Grossman, AB; Donnell, D

• Publication status: Published
• Host title: Respiratory medicine
• Volume: 92 Suppl A
• Issue: SUPPL. A
• Pages: 33-39
• Publication date: 1998-06-01
• Event location: ENGLAND
• DOI: 10.1016/s0954-6111(98)90215-3
• EISSN: 1532-3064
• ISSN: 0954-6111
• Keywords: Chlorofluorocarbons; Adolescent; Anti-Inflammatory Agents; Cosyntropin; Aged; Hydrocarbons, Fluorinated; Drug Administration Schedule; Humans; Cross-Over Studies; Pituitary-Adrenal System; Asthma; Middle Aged; Hydrocortisone; Beclomethasone; Aerosol Propellants; Cough; Hypothalamo-Hypophyseal System; Adult; Administration, Inhalation